Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 06-Oct-2017

IXICO today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors (wearable biosensors) in a Phase II clinical trial for a neurological disorder.

This is IXICOs first commercial agreement using activity sensors to evaluate exploratory digital measures in early phase clinical research and follows a presentation of IXICOs approach to measuring sleep disturbances at the Mobile devices for clinical trials in neurological diseases workshop earlier this year at the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD) meetings.

This contract has a value of around 0.5m over a two year term, commencing in September 2017. IXICO will utilise its biosensor clinical trial capabilities, combined with its artificial intelligence data analytics algorithms, to measure activity and sleep disturbances from biosensor data collected from c.300 people.

Sleep disturbance is a challenging symptom of many brain diseases including Parkinsons and Alzheimers Disease and is also a side effect of many drug treatments. The work performed in this clinical trial, represents an important step in the validation of biosensors as new digital technologies in a specific context of use, as required by regulatory authorities.

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be deploying wearable biosensors and our proprietary algorithms to measure sleep disturbance in a commercial clinical trial. This is an excellent opportunity for IXICO to demonstrate how our biosensor services and technology, build upon our well-established expertise in providing regulatory compliant imaging endpoints in clinical trials, to support the process of developing new drugs to treat neurological diseases."

Go to previous page